US50127T1097
© Globe Newswire
08.12.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
News Preview
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
KURA
LISTED
NASDAQ
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
News Preview
Event Scheduled for December 8, 2025 at 12:30 PM ET Event Scheduled for December 8, 2025 at 12:30 PM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
KURA
LISTED
NASDAQ
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
News Preview
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement wi...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
25.11.2025
KURA
LISTED
NASDAQ
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
News Preview
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
13.11.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
News Preview
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
KURA
LISTED
NASDAQ
Kura Oncology to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensati...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
KURA
LISTED
NASDAQ
Kura Oncology Reports Third Quarter 2025 Financial Results
News Preview
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
KURA
LISTED
NASDAQ
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
News Preview
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- ...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
KURA
LISTED
NASDAQ
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
News Preview
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on October 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
News Preview
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
29.09.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
News Preview
– KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval –...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
News Preview
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses –...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
KURA
LISTED
NASDAQ
Kura Oncology to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
KURA
LISTED
NASDAQ
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
News Preview
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensa...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
KURA
LISTED
NASDAQ
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
News Preview
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
News Preview
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients –...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.06.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
News Preview
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial –...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
News Preview
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
News Preview
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th –...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
News Preview
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
News Preview
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
– Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
News Preview
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
– Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
News Preview
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
– Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
News Preview
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
– Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
News Preview
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
KURA
LISTED
NASDAQ
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
News Preview
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
KURA
LISTED
NASDAQ
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
News Preview
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled “Ziftomeni...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.07.2024
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation C...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
KURA
LISTED
NASDAQ
Kura Oncology Reports First Quarter 2024 Financial Results
News Preview
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML –...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
